Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R‐<scp>GEM</scp>‐P) is an effective regimen in relapsed diffuse large B‐cell lymphoma

Abstract

R-GEM-P is a deliverable regimen with useful activity in second-line treatment of DLBCL. Our data suggest that rituximab should be given concurrently.